Is Tenet Healthcare (THC) Overvalued Following Higher 2026 Adjusted EPS Guidance?
Tenet Healthcare (THC) is back in focus after reporting a technical golden cross in its share price, alongside higher earnings estimates and an increase in its 2026 adjusted EPS guidance.
See our latest analysis for Tenet Healthcare.
For context, Tenet Healthcare’s share price has risen sharply in recent months, with a 30 day share price return of 45.38% and a year to date share price return of 33.89%, while the 1 year total shareholder return sits at 54.94%. This points to strong momentum layered on top of multi year gains.
If this kind of momentum in healthcare catches your eye, it can be useful to see what else is moving in the space by scanning 44 healthcare AI stocks.
After a run that has pushed Tenet Healthcare close to some analyst targets, yet still far below certain intrinsic value estimates, the real question is where fair value sits across that spread as the valuation work starts.
Most Popular Narrative: 7% Overvalued
Tenet Healthcare’s most followed valuation narrative sets fair value at $250, compared with a last close of $267.05, which puts the stock slightly above that line in the sand based on those assumptions.
The bearish analysts expect earnings to reach $1.2 billion (and earnings per share of $17.84) by about August 2029, down from $2.2 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $1.7 billion.
Want to see what justifies that valuation gap? The narrative leans on slower revenue growth, thinner margins, and a higher future earnings multiple. Curious which assumptions really drive that fair value call.
Result: Fair Value of $250 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Tenet Healthcare could still surprise this bearish view if cost control holds up more firmly than expected or if high acuity volumes and M&A contributions outperform.
Find out about the key risks to this Tenet Healthcare narrative.
Another View On Tenet Healthcare’s Valuation
Compared with the $250 fair value from the bearish narrative, Tenet Healthcare looks very different on earnings multiples. The stock trades on a P/E of 9.6x versus 24.8x for the US Healthcare industry and 20.3x for peers, while the fair ratio for THC is 17.9x. That is a wide gap that could either signal mispricing or reflect the high debt load and forecast earnings decline. Which explanation do you find more convincing?
For a closer look at how valuation could shift if the market relies more on earnings and cash flow math, take a look at our breakdown in See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Sentiment around Tenet Healthcare is clearly mixed, with strong price momentum set against both risks and rewards identified in the story so far. If you want to act while the market is still debating the outlook, it helps to review the details behind the 3 key rewards and 3 important warning signs.
Looking for more investment ideas beyond Tenet Healthcare?
If Tenet Healthcare has you thinking more broadly about your portfolio, now is a good time to line up fresh ideas that fit different goals and risk levels.
- Target potential turnaround opportunities by scanning 20 elite penny stocks with strong financials that already show stronger balance sheets and fundamentals than many expect from this corner of the market.
- Strengthen your core holdings by reviewing solid balance sheet and fundamentals stocks screener (49 results) that pair resilient finances with business models designed to handle tougher conditions.
- Get ahead of the crowd by checking the screener containing 18 high quality undiscovered gems before more investors start paying attention to these profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com